Screener
Cytokinetics CYTK Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's total liabilities?
- Cytokinetics (CYTK) reported total liabilities of $2.1B in Q2 2026.
- How has Cytokinetics's total liabilities changed year-over-year?
- Cytokinetics's total liabilities increased by 31.6% year-over-year, from $1.59B to $2.1B.
- What is the long-term trend for Cytokinetics's total liabilities?
- Over 5 years (2020 to 2025), Cytokinetics's total liabilities has grown at a 37.7% compound annual growth rate (CAGR), from $420.42M to $2.08B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Cytokinetics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude